Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls a multicenter study

Annals of Surgery

Volumn 263, Issue 6, 2016, Pages 1173-1179

  Xu, Jianwei ^a   Cao, Zhe ^a   Liu, Wenjing ^a   You, Lei ^a   Zhou, Li ^a   Wang, Chunyou ^b   Lou, Wenhui ^c   Sun, Bei ^d   Miao, Yi ^e   Liu, Xubao ^f   Zhang, Taiping ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

Author keywords

Circulating miRNA; Diagnosis; Multicenter study; Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; MICRORNA; MICRORNA 486 5P; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTICENTER STUDY; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; CASE CONTROL STUDY; CHINA; CHRONIC DISEASE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; MIDDLE AGED; PANCREAS TUMOR; REAL TIME POLYMERASE CHAIN REACTION;

AGED; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CHINA; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84949540009     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001345     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
3. von Rosen A, Linder S, Harmenberg U, et al. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas. 1993;8:160-165.
4. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive bio-markers in pancreatic cancer. J Surg Oncol. 2013;107:15-22.
5. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143-159.
6. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901-1908.
7. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54:1716-1724.
8. Schultz NA, Werner J, Willenbrock H, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol. 2012;25:1609-1622.
9. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem. 2010;56: 603-612.
10. Ryu JK, Hong SM, Karikari CA, et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10:66-73.
11. Yu J, Li A, Hong SM, et al. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res. 2012;18:981-992.
12. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
13. Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19:3600-3610.
14. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311:392-404.
15. Vosa U, Vooder T, Kolde R, et al. Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2013;132:2884-2893.
16. Patnaik SK, Yendamuri S, Kannisto E, et al. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS One. 2012;7:e46045.
17. Fassina A, Marino F, Siri M, et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Lab Invest. 2012;92:1574-1582.
18. Ali S, Saleh H, Sethi S, et al. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer. 2012;107:1354-1360.
19. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844-852.
20. Wang Y, Tang N, Hui T, et al. Identification of endogenous reference genes for RT-qPCR analysis of plasma microRNAs levels in rats with acetaminophen-induced hepatotoxicity. J Appl Toxicol. 2013;33:1330-1336.
21. Benz F, Roderburg C, Vargas Cardenas D, et al. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med. 2013;45:e42.
22. Zheng G, Wang H, Zhang X, et al. Identification and validation of reference genes for qPCR detection of serum microRNAs in colorectal adenocarcinoma patients. PLoS One. 2013;8:e83025.
23. Song J, Bai Z, Han W, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci. 2012;57:897-904.
24. Szabo DR, Luconi M, Szabo PM, et al. Analysis of circulating microRNAs in adrenocortical tumors. Lab Invest. 2014;94:331-339.
25. Ell B, Mercatali L, Ibrahim T, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24:542-556.
26. Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013;73:4801-4809.
27. Liu Y, Zhou Y, Feng X, et al. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer. Genes Chromosomes Cancer. 2014;53:358-365.
28. Butz H, Liko I, Czirjak S, et al. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary. 2011;14:112-124.
29. Ragusa M, Statello L, Maugeri M, et al. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK(ERK inhibitors. J Mol Med (Berl). 2012;90:1421-1438.
30. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010;42:1348-1354.
31. Wang F, Li T, Zhang B, et al. MicroRNA-19a(b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 2013;434:688-694.
32. Peng Y, Dai Y, Hitchcock C, et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci USA. 2013;110:15043-15048.
33. Mees ST, Mardin WA, Sielker S, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol. 2009;16:2339-2350.
34. Tahiri A, Leivonen SK, Luders T, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 2014;35:76-85.
35. Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110:2291-2299.
36. Ahmed FE, Ahmed NC, Vos PW, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics. 2013;10:93-113.